Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Trial Identifier: D967YC00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo, Inc.
Start Date: March 2021
Primary Completion Date: June 2027
Study Completion Date: June 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Adelaide, AU, 5000
AU Nedlands, AU, 6009
BE Edegem, BE, 2650
BR Porto Alegre, BR, 90035-903
CA, QC Montreal, QC, CA, H3T 1E2
FR Dijon, FR, 21079
FR Pierre-Benite, FR, 69495
FR SAINT HERBLAIN, FR, 44800
FR Villejuif Cedex, FR, 94805
IL Kfar-Saba, IL, 4428164
IL Tel Hashomer, IL, 52620
IT Milano, IT, 20133
IT Milano, IT, 20162
IT Monza, IT, 20052
IT Napoli, IT, 80131
IT Padova, IT, 35128
KR Cheongju-si, KR, 28644
KR Goyang-si, KR, 10408
KR Jinju-si, KR, 52727
KR Seoul, KR, 06351
KR Seoul, KR, 03722
MY George Town, MY, 10450
MY Kuala Lumpur, MY, 59100
MY Kuching, MY, 93586
MY Selangor, MY, 62250
NL Amsterdam, NL, 1066 CX
PH Bacolod, PH, 6100
PH Davao City, PH, PH-8000
PH Manila, PH, 1000
PH Quezon City, PH, 1112
PH Quezon City, PH, 1100
PH San Juan, PH, 1500
PL Gdańsk, PL, 80-214
PL Kraków, PL, 30-727
PL Olsztyn, PL, 10-357
PL Tomaszów Mazowiecki, PL, 97-200
PL Warszawa, PL, 02-781
SG Singapore, SG, 119228
SG Singapore, SG, 308433
SG Singapore, SG, 168583
TH Bangkok, TH, 10300
TH Bangkok, TH, 10330
TH Hat Yai, TH, 90110
TH Khon Kaen, TH, 40002
TH Muang, TH, 50200
TR Ankara, TR, 06800
TR Ankara, TR, 6200
TR Bornova-Izmir, TR, 35100
TW Kaohsiung city, TW, 833
TW Taichung, TW, 40705
TW Taichung City, TW, 402
TW Tainan, TW, 70403
TW Taipei, TW, 11217
TW Taipei, TW, 100
TW Taipei, TW, 235
TW Taoyuan, TW, 333
US, CA Orange, CA, US, 92868
US, MD Baltimore, MD, US, 21287
US, TX Houston, TX, US, 77030
US, VA Fairfax, VA, US, 22031
US, WA Tacoma, WA, US, 98405